ClinicalTrials.gg
CompletedNCT00088621Updated Apr 17, 2014Results posted

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

A Phase 2 interventional study of Lurasidone 80mg tablet in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-04-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
25th of 39
61 · median 149
Started
2004
with 1 other
Phase 2
5 of 39
none open now
Registered
3rd of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 25th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 2, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia

Read the detailed description

Study will evaluate long-term safety and tolerability of a new compound in the treatment of patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal symptoms (EPS; Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Scale [BAS], and Simpson-Angus Rating Scale [SAS]), vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either:
  • Successfully completed
  • OR
  • Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Lurasidone 80 mg tablet

    Lurasidone 80mg oral tablet taken once a day

    Drug: Lurasidone 80mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study

    Time frame: 1 year

07

Results

Posted May 6, 2011

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 80 mg
Started61
Completed7
Not completed54

Outcome measures

PrimaryNumber of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study
Time frame:
1 year
Reported as:
Number · participants
Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study
participantsLurasidone 80 mg
Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study59

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 80 mg—12/59 (20.3%)18/59 (30.5%)
Most frequent serious events
Most frequent serious events
EventLurasidone 80 mg
SchizophreniaPsychiatric disorders8/59
Pericardial EffusionCardiac disorders1/59
OrchitisInfections and infestations1/59
PneumoniaInfections and infestations1/59
SepsisInfections and infestations1/59
Cerebrovascular AccidentNervous system disorders1/59
Self Injurious BehaviorPsychiatric disorders1/59
ProstatitisReproductive system and breast disorders1/59
Pulmonary MassRespiratory, thoracic and mediastinal disorders1/59
Most frequent other events
Most frequent other events
EventLurasidone 80 mg
NauseaGastrointestinal disorders4/59
BronchitisInfections and infestations4/59
Weight IncreasedInvestigations4/59
SedationNervous system disorders4/59
VomitingGastrointestinal disorders3/59
NasopharyngitisInfections and infestations3/59
Upper Respiratory Tract InfectionInfections and infestations3/59
Weight DecreasedInvestigations3/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lurasidone 80 mg
Mean41.3 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 80 mg
Female15
Male44
Region of Enrollment
Region of Enrollment(participants)Lurasidone 80 mg
United States59
08

Study locations

21 sites
  • Birmingham Psychiatry Pharmaceutical
    Birmingham, Alabama 35209, United States
  • Summit Research Group
    Little Rock, Arkansas 72211, United States
  • Comprehensive NeuroScience
    Cerritos, California 90703, United States
  • Collaborative Neuro Science Network, Inc.
    Garden Grove, California 92845, United States
  • Optimum Health Services
    La Mesa, California 91942, United States
  • California Clinical Trials
    San Diego, California 92123, United States
  • CA Neutopsychopharmacology Clinical Research Institute (CNRI)
    San Diego, California 92126, United States
  • Pacific Clinical Research
    Upland, California 91786, United States
  • Comprehensive NeuroScience, Inc
    Washington, District of Columbia 20016, United States
  • Segal Institute for Clinical Research
    Fort Lauderdale, Florida 33301, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • University of South Florida, Department of Psychiatry and Behavioral Medicine
    Tampa, Florida 33613, United States
  • Comprehensive Neuroscience, Inc.
    Hoffman Estates, Illinois 60194, United States
  • Las Vegas, Nevada 89102, United States
  • CNS Research Institute
    Clementon, New Jersey 08021, United States
  • Quantum Clinical Services Group
    Philadelphia, Pennsylvania 19139, United States
  • Community Clinical Research
    Austin, Texas 78729, United States
  • Future Search Trials
    Austin, Texas 78756, United States
  • Claghorn Lesem Research Clinic, Inc.
    Bellaire, Texas 77401, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • CBH Health, L.L.C - Dominion Hospital
    Falls Church, Virginia 22044, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2004
First posted
Aug 2, 2004
Start
Jul 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
May 6, 2011
Last update
Apr 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00088621
Responsible party
Sponsor
First posted
Aug 2, 2004
Start date
Jul 2004
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
May 6, 2011
Last update
Apr 17, 2014

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion